LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Cytotoxic chemotherapy is usually scaled to the body surface area (BSA), and is currently not
adjusted to the body proportions of lean and fat (i.e. body composition) of individual
patients. Patients with low muscle mass behave like patients "overdosed" with chemotherapy
resulted in dose-limiting toxicities (e.g. dose reductions, treatment delays or permanent
treatment discontinuation), independently of the patient's weight.